Skip to content
A Free Live Webinar

Dispelling Myths, Controversies,
& Urban Legends in EGFRm NSCLC
Promoting Evidence-Based Communication between Clinicians, Researchers, and Patient Advocates

WordCloud
A Free Live Webinar

Dispelling Myths, Controversies, & Urban Legends in EGFRm NSCLC Promoting Evidence-Based Communication between Clinicians, Researchers, and Patient Advocates

WordCloud

Invite your oncology team members to this free virtual event!

This live webinar is accredited for physicians, nurses, pharmacists, and physician assistants. Click the social links below to share!

Presented by Creative Educational Concepts, Inc. in collaboration with the EGFR Resisters Lung Cancer Patient Group .Supported through an independent educational grant from AstraZeneca.
Presented by Creative Educational Concepts, Inc.
in collaboration with the EGFR Resisters Lung Cancer Patient Group .
Supported through an independent educational grant from AstraZeneca.
Presented by Creative Educational Concepts, Inc. in collaboration with the EGFR Resisters Lung Cancer Patient Group . Supported through an independent educational grant from AstraZeneca.
Presented by Creative Educational Concepts, Inc. in collaboration with the EGFR Resisters Lung Cancer Patient Group . Supported through an independent educational grant from AstraZeneca.

Activity Information

This engaging live webinar will convene a panel of thoracic oncologists, researchers, and patient advocates to consider current controversies in EGFRm NSCLC arising from the emergence of rapidly evolving science and social media.

COVID-19 has added a layer of complexity to decision-making in 2020. Has it also changed what we consider as standards of clinical practice?

Collage2

Agenda

  • 7:00 PM - 7:10 PM

    Welcome & Introductions

  • 7:10 PM - 8:40 PM

    Presentations

    Myth 1: There’s no need to wait for biomarker testing on new patients anymore with all the new immunotherapies out there.

    Myth 2: I’ve heard it’s best to keep osimertinib as 2nd line therapy and start with a 1st/2nd generation EGFR TKI.

    Myth 3: Liquid biopsies have replaced tissue biopsies to find biomarkers at the time of resistance.

    Myth 4: Whole brain radiation for brain mets is the best option.

    Myth 5: Once osimertinib treatment stops working, I have no other options.

    Myth 6: Clinical trials are for people in the city or at big cancer centers.

  • 8:40 PM - 9:00 PM

    Q&A

Agenda

Welcome & Introductions

7:00 PM – 7:10 PM

Presentations

7:10 PM – 8:40 PM

Myth 1: There’s no need to wait for biomarker testing on new patients anymore with all the new immunotherapies out there.

Myth 2: I’ve heard it’s best to keep osimertinib as 2nd line therapy and start with a 1st/2nd generation EGFR TKI.

Myth 3: Liquid biopsies have replaced tissue biopsies to find biomarkers at the time of resistance.

Myth 4: Whole brain radiation for brain mets is the best option.

Myth 5: Once osimertinib treatment stops working, I have no other options.

Myth 6: Clinical trials are for people in the city or at big cancer centers.

Q&A

8:40 PM – 9:00 PM

Faculty

Jointly_Accredited_Provider_PNG

Accreditation

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.